Loading market dashboard
Scancell Holdings plc
SCNLFHealthcareOTCGB
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Panmure Liberum holds its 'buy' rating and 32p target as FDA fast-track status adds regulatory momentum to compelling trial data. Scancell Holdings PLC...
Panmure Liberum holds its 'buy' rating and 32p target as FDA fast-track status adds regulatory momentum to compelling trial data. Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) shares rose 5.3% to 13.69p on Tuesday as the cancer immunotherapy developer delivered a double dose of positive news.
The AIM-listed biotech reports 77% progression-free survival at 20 months, well ahead of the standard of care Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the cancer immunotherapy developer, has secured a Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead drug candidate, iSCIB1+, in advanced melanoma.
Potent and durable efficacy with iSCIB1+ of 77% progression free survival (PFS) at 20 months, in combination with ipilimumab and nivolumab, demonstrated in the Phase 2 SCOPE trial; more PFS and additional early overall survival (OS) data expected in H1 2027
Major US banks are poised to deliver solid first quarter results, though broader economic concerns may temper investor enthusiasm as earnings season begins,...
Neurocrine Biosciences (NASDAQ:NBIX) has agreed to acquire Soleno Therapeutics (NASDAQ:SLNO) in an all-cash transaction valued at approximately $2.9...
Near-term consolidation is creating buying opportunities, but silver, platinum and palladium face growing headwinds if oil prices tip the global economy...
12:05pm: Auto deliveries a mixed bad US automakers reported a mixed bag of vehicle deliveries in the first quarter, with Tesla and Ford seeing sales...
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), th cancer immunotherapy developer, has named David Schilansky as financial adviser and interim chief...
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), th cancer immunotherapy developer, has named David Schilansky as financial adviser and interim chief financial officer as current CFO Sath Nirmalananthan prepares to leave the company. Nirmalananthan will step down from the board on 24 April to pursue other opportunities, with Schilansky taking on the interim CFO role later in April while a global search for a permanent replacement gets under way.
